Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @CaPsurvivorship
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @CaPsurvivorship
-
Alicia Morgans proslijedio/la je Tweet
Fibroblast growth factor receptor 3 alterations and response to PD-1/PD-L1 blockade in patients with metastatic urothelial cancer.
@MattGalsky@TischCancer and@CaPsurvivorship@NUFeinbergMed discussion on UroToday now. http://bit.ly/2l189J6 pic.twitter.com/oDMB3wpq4f
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Outstanding talk by
@DrSpratticus at the University of Minnesota’s Prostate Cancer Symposium. Thank you for making treatment decisions so clear for us!#minnesotaprostatecancer@EHeath4100@charlesryanmd@urotodayHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
So honored to be involved with
@NM_Urology and@UsTOOHQ to participate in@SEABlueWalkRun this year! Thanks to@PeteMcMurray and@WGNRadio for talking about the event and men’s health last night!https://wgnradio.com/2019/09/10/northwestern-hospitals-dr-alicia-morgans-helps-keep-our-prostates-healthy/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Thank you all for providing a framework for PRO research in oncology. Standardizing a robust research approach is the first step in making data interpretable and useful to the millions of men and women dealing with cancer treatment decisions each day.
#estimands#OCEOutcomes19https://twitter.com/BellKingKal/status/1149730352895791104 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The things that matter to kids likely matter to all of us. Let’s be kinder, enjoy time together, get to the beach, and definitely eat more ice cream. Life can be bigger and better. Take small steps.https://twitter.com/gulleyj1/status/1144920510591119360 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
One of the clearest minds in the field,
@PGrivasMDPhD shares his insights with brilliance and compassion. I have no doubt we will continue to move the needle with him in our midst.https://twitter.com/TiansterZhang/status/1135308627261251584 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Completely agree with you
@maughanonc . Hoping you’ll join the charge and help us educate, anticipate, and create guidelines to ensure the best balance of efficacy and toxicity. Rapid identification of these complications is still too late for some.https://twitter.com/maughanonc/status/1135686587013111809 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
If you missed it, be sure to watch virtual meeting
@TDorffOnc review what we can and cannot conclude after hearing the ENZAMET outcomes. As always, excellent work.#ASCO19https://twitter.com/FaltasLab/status/1135275306405826560 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
”Disparities May Be exacerbated by the increasing focus on precision medicine.”
@HalaBorno If we don’t include racially diverse patients in genomic testing, we are not able to precisely target the variants in minority populations. Inclusion is key.pic.twitter.com/PLQL3e07jY
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
@HalaBorno outlines the challenges of disparities in prostate cancer care and trials in the US, including a framework for progress.#ASCO19pic.twitter.com/AWPG07YHHC
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Silke Gillessen kicks off the prostate cancer disparities session in S100a, highlighting differences in access between and within countries. Lots of work to be done!
#ASCO19pic.twitter.com/GnL2nPJYD6
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Neha Vapiwala delivers a comprehensive review of approaches to oligometastatic prostate cancer, injecting hope and strong scientific rationale into the process.
#ASCO19pic.twitter.com/6CCFskRjj3
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
@EdwardSchaeffer reminds us of the benefits of slowing oligoprgression in prostate cancer. Change the natural course of the disease, improve outcomes.#ASCO19pic.twitter.com/EcANtwiPzD
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Join us in B1 with
@EdwardSchaeffer to review the latest data guiding treatment of oligometastatic prostate cancer! Bright and early!#ASCO19pic.twitter.com/YfQnzibTrr
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Julie Graff artfully walks us through abstracts in the poster discussion
#ASCO19pic.twitter.com/wqAtejjowD
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Scott Williams implores us to prepare for the PSMA tsunami by designing smart trials to study the effects and populations most likely to benefit.
#ASCO19pic.twitter.com/iT3hnweR2W
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Alicia Morgans proslijedio/la je Tweet
Looking forward to being part of (an otherwise) great panel in S406 shortly - what do people think about when choosing and sequencing treatments for
#ProstateCancer, in an era where several therapies are now approved for M0 CRPC?#ASCO19Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Mark Fleming, Dana Rathkopf, Fred Saad, and Ian Davis present their diverse views on the complicated treatment of nmCRPC and downstream effects of treatment. Join the tumor board
#ASCO19 !pic.twitter.com/6Lj0Kv7Jws
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Excellent review of negative trial that still enlightens - don’t use abi and enza simultaneously, but always include additional critical questions when designing studies. Alliance again demonstrates correlation between rPFS and OS despite neg study.
#ASCO19pic.twitter.com/8x1hcLe7h4
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Bertrand Tombal shares PEACE-3 experience - mandating bone health treatments resulted in a large reduction in SSE, improving patient outcomes with standard of care approach.
#ASCO19pic.twitter.com/R7mK4obCaD
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.